Construction of data for implementation of comprehensive cancer genome profiling using genome-guided system

Construction of data for implementation of comprehensive cancer genome profiling using genome-guided system - Construction of data for implementation of comprehensive cancer genome profiling using genome-guided system

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052151

Enrollment

200

Registered

2023-09-08

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases that meet all of the following are eligible 1. Solid cancer cases 2. Cases undergoing cancer gene panel testing using the MH Guide at St. Marianna University Hospital

Exclusion criteria

Exclusion criteria: Cases judged by the principal investigator to be inappropriate for participation in the study

Design outcomes

Primary

Measure	Time frame
Rate of patients for whom genome-guided treatment could be proposed among patients who underwent cancer gene panel testing at St. Marianna University Hospital and were analysed using the MH Guide for annotation based on measured data.	—

Secondary

Measure	Time frame
druggable genomic alterations Definition in the St. Marianna University Hospital Expert Panel: genomic alterations with evidence level C1 or higher or evidence level D2 and promising investigational drugs in the Guidance for cancer treatment based on gene panel testing using next-generation sequencers. Definition in the MH Guide: genomic alterations with a Biomarker score of 4 or more. Time spent on annotation.	—

Measure

Time frame

druggable genomic alterations *Definition in the St. Marianna University Hospital Expert Panel: genomic alterations with evidence level C1 or higher or evidence level D2 and promising investigational drugs in the Guidance for cancer treatment based on gene panel testing using next-generation sequencers. *Definition in the MH Guide: genomic alterations with a Biomarker score of 4 or more. Time spent on annotation.

—

Countries

Japan

Contacts

Public ContactKiyomi Imoto

St. Marianna University Hospital Centre for the Genomic Medicine

imoto@marianna-u.ac.jp0449778111

Outcome results